Integrin Research The Martin Humphries Lab

Antibody affinity maturation and plasma IgA associate with clinical outcome in hospitalized COVID-19 patients

Hospitalized COVID-19 sufferers usually current with a big spectrum of scientific signs. There’s a vital want to raised perceive the immune responses to SARS-CoV-2 that result in both decision or exacerbation of the scientific illness. Right here, we study longitudinal plasma samples from hospitalized COVID-19 sufferers with differential scientific consequence. We carry out immune-repertoire evaluation together with cytokine, hACE2-receptor inhibition, neutralization titers, antibody epitope repertoire, antibody kinetics, antibody isotype and antibody affinity maturation towards the SARS-CoV-2 prefusion spike protein.

Deadly circumstances reveal excessive plasma ranges of IL-6, IL-8, TNFα, and MCP-1, and sustained excessive share of IgA-binding antibodies to prefusion spike in contrast with non-ICU survivors. Illness decision in non-ICU and ICU sufferers associates with antibody binding to the receptor binding motif and fusion peptide, and antibody affinity maturation to SARS-CoV-2 prefusion spike protein. Right here, we offer perception into the immune parameters related to scientific illness severity and disease-resolution consequence in hospitalized sufferers that would inform improvement of vaccine/therapeutics towards COVID-19.

Kaposi sarcoma in anti-neutrophil cytoplasmic antibody-associated vasculitis: a case-based evaluation

Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) are systemic necrotizing vasculitides related to important morbidity and mortality. Given the immunosuppression used to handle these situations, it will be important for clinicians to acknowledge issues, particularly infectious ones, which can come up throughout therapy. Kaposi sarcoma (KS) is a lymphoangioproliferative neoplasm attributable to human herpes virus 8 (HHV-8). Its cutaneous manifestations can mimic vasculitis.

We describe a 77-year-old man with microscopic polyangiitis with pulmonary-renal syndrome handled with prednisone and intravenous cyclophosphamide who developed KS (HHV-Eight constructive) after 2 months of therapy. Cyclophosphamide was discontinued and prednisone step by step lowered with enchancment and scientific stabilization of KS lesions.

This complete evaluation contains all revealed circumstances of KS in sufferers with AAV, with a aim to summarize potential danger components together with the scientific traits of vasculitis, therapy and outcomes of sufferers with this uncommon complication of immunosuppressive remedy. We additionally expanded our literature evaluation to KS in different types of systemic vasculitis. Our case-based evaluation emphasizes the significance of contemplating infectious issues of immunosuppressive remedy, particularly glucocorticoids, and highlights the uncommon affiliation of KS in systemic vasculitis.

Aggressive Immunoassay of SARS-CoV-2 Utilizing Pig Sera-Derived Anti-SARS-CoV-2 Antibodies

Anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) nucleoprotein (NP) antibodies have been remoted from pig sera utilizing human SARS-CoV-2 NP-immobilized magnetic beads. The binding properties of the remoted antibodies towards SARS-CoV-2 NP have been examined by way of movement cytometry utilizing SARS-CoV-2 NP-immobilized magnetic beads. A aggressive immunoassay was developed for detecting SARS-CoV-2 NP in addition to SARS-CoV-2 within the tradition fluid utilizing magnetic beads with immobilized anti-SARS-CoV-2 NP antibodies. Selectivity assessments have been carried out throughout the aggressive immunoassay for SARS-CoV, MERS-CoV, and CoV pressure 229E within the tradition fluid.

Discount in Nesfatin-1 Ranges within the Cerebrospinal Fluid and Elevated Nigrostriatal Degeneration Following Ventricular Administration of Anti-nesfatin-1 Antibody in Mice

Nesfatin-1 is one among a number of brain-gut peptides which have a detailed relationship with the central dopaminergic system. Our earlier research have proven that nesfatin-1 is able to defending nigral dopaminergic neurons towards 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity. A current research additionally revealed a diminished blood degree of nesfatin-1 in sufferers with Parkinson’s illness (PD). The present research was designed to analyze whether or not diminished nesfatin-1 in cerebrospinal fluid (CSF) induces nigrostriatal system degeneration.

An intra-cerebroventricular (ICV) injection approach was used to manage anti-nesfatin-1 antibody straight into the lateral ventricle of the mind. Enzyme-linked immunosorbent assay (ELISA) outcomes confirmed that ICV injection of anti-nesfatin-1 antibody into the lateral ventricle of the mind as soon as day by day for two weeks precipitated a major discount in nesfatin-1 ranges within the CSF (93.1%).

Remedy with anti-nesfatin-1 antibody resulted in a considerable loss (23%) of TH-positive (TH+) dopaminergic neurons within the substantia nigra pars compacta (SNpc), as proven by immunofluorescence staining, a depletion in dopamine and its metabolites within the striatum detected by high-performance liquid chromatography (HPLC), and apparent nuclear shrinkage and mitochondrial lesions in dopaminergic neurons within the SNpc detected by transmission electron microscopy (TEM).

Moreover, the outcomes from our Western blot and ELISA experiments demonstrated that anti-nesfatin-1 antibody injection induced an upregulation of caspase-Three activation, elevated the expression of p-ERK, and elevated brain-derived neurotrophic issue (BDNF) ranges within the SNpc. Taken collectively, these observations recommend that diminished nesfatin-1 within the mind could induce nigrostriatal dopaminergic system degeneration; this impact could also be mediated by way of mitochondrial dysfunction-related apoptosis. Our information help a task of nesfatin-1 in sustaining the conventional physiological perform of the nigrostriatal dopaminergic system.

Convergent antibody evolution and clonotype enlargement following influenza virus vaccination

Current advances in high-throughput single cell sequencing have opened up new avenues into the investigation of B cell receptor (BCR) repertoires. On this research, PBMCs have been collected from 17 human contributors vaccinated with the split-inactivated influenza virus vaccine throughout the 2016-2017 influenza season. A mix of Immune Repertoire Seize (IRCTM) expertise and IgG sequencing was carried out on ~7,800 plasmablast (PB) cells and preferential IgG heavy-light chain pairings have been investigated. In some contributors, a single expanded clonotype accounted for ~22% of their PB BCR repertoire.

Roughly 60% (10/17) of contributors skilled convergent evolution, possessing public PBs that have been elicited independently in a number of contributors. Binding profiles of 1 non-public and three public PBs confirmed they have been all subtype-specific, cross-reactive hemagglutinin (HA) head-directed antibodies.

Human IL23A/p19 Neutralizing Antibody
MBS8113352-02mg	MyBiosource	0.2mg	EUR 280

Human IL23A/p19 Neutralizing Antibody
MBS8113352-05mg	MyBiosource	0.5mg	EUR 375

Human IL23A/p19 Neutralizing Antibody
MBS8113352-5x05mg	MyBiosource	5x0.5mg	EUR 1545

Anti-BTLA Neutralizing Antibody
100244	BPS Bioscience	100 µg	EUR 355
Description: This anti-BTLA antibody is a purified recombinant human monoclonal antibody which recognizes the human BTLA protein. BTLA (B- and T-lymphocyte attenuator) belongs to the CD28 immunoglobulin superfamily (IgSF) and is an immune-regulatory receptor that binds to HVEM (Herpesvirus entry mediator, also known as TNFRSF14, Tumor necrosis factor receptor superfamily member 14). This antibody has been tested for specific binding to purified human BTLA protein and neutralizes the interaction between BTLA and HVEM.

Anti-VEGF Neutralizing Antibody
79478-1	BPS Bioscience	50 µg	EUR 355
Description: Anti-VEGF recombinant Human antibody. This antibody not been tested for cross-reactivity with other species.

Anti-VEGF Neutralizing Antibody
79478-2	BPS Bioscience	100 g	EUR 460
Description: Anti-VEGF recombinant Human antibody. This antibody not been tested for cross-reactivity with other species.

Anti-LAG3, Neutralizing Antibody
71219	BPS Bioscience	100 µg	EUR 530
Description: Neutralizing recombinant human antibody recognizing the Lag-3 binding region.

Anti-RANKL Neutralizing Antibody
100874-1	BPS Bioscience	50 µg	EUR 335
Description: Human, recombinant monoclonal antibody recognizing the RANKL protein, also known as TNFSF11 antibody and CD254 antibody. This antibody recognizes human RANKL. It has not been tested with other species. MW= 50 kDa (Heavy chain); 24 kDa (Light chain).

Anti-RANKL Neutralizing Antibody
100874-2	BPS Bioscience	100 µg	EUR 460
Description: Human, recombinant monoclonal antibody recognizing the RANKL protein, also known as TNFSF11 antibody and CD254 antibody. This antibody recognizes human RANKL. It has not been tested with other species. MW= 50 kDa (Heavy chain); 24 kDa (Light chain).

Anti-VISTA Neutralizing Antibody
101293	BPS Bioscience	100 µg	EUR 450
Description: This human monoclonal antibody recognizes human V-domain immunoglobulin (Ig) suppressor of T cell activation (VISTA), and neutralizes its interaction with VSIG3 (also called IGSF11). VISTA is also known as B7-H5 or VSIR (GenBank Accession No. NM_022153). VSIG3 is a ligand involved in cell adhesion as a VISTA binding partner. This neutralizing antibody has been functionally tested using the VSIG-3:VISTA [Biotinylated] Inhibitor Screening Assay Kit (BPS Bioscience #79782).

Anti-PCSK9 Neutralizing Antibody
71207	BPS Bioscience	50 µg	EUR 555
Description: Neutralizing recombinant human antibody (IgG1) recognizing the LDLR binding region of human PCSK9.

Anti-TIGIT Neutralizing Antibody
71340	BPS Bioscience	100 µg	EUR 565
Description: Human Anti-TIGIT neutralizing antibody recognizing the TIGIT binding region on immune cells.

Anti-BCMA Neutralizing Antibody, Mouse IgG1 (recommended for neutralizing assay)
BCA-M43	ACROBIOSYSTEMS	100ug	EUR 2354
Description: Anti-BCMA Neutralizing Antibody, is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with BCMA.

Anti-PD-1 Neutralizing Antibody
71120	BPS Bioscience	100 µg	EUR 465
Description: Neutralizing recombinant murine/human chimeric antibody recognizing the PD-L1/PD-L2 binding region of human PD-1. This antibody does not cross-react with mouse PD-1, but does cross-react with monkey (M. fascicularis) PD-1. It has not been tested with other species.

Interferon Beta Human Neutralizing, Antibody
GWB-A7C102	GenWay Biotech	0.5 mg	Ask for price

Anti-IL-17A Neutralizing Antibody
91015	BPS Bioscience	100 µg	EUR 490
Description: Neutralizing recombinant human_x000D_chimeric antibody recognizing human IL-17A._x000D_This antibody has not been tested for crossreactivity_x000D_with other species.

Human Cells anti-COVID-19 S-IgM Neutralizing Antibody
DL99728A-100ul	DL Develop	100 ul	EUR 299
Description: Spike glycoprotein; S glycoprotein; E2; Peplomer protein

Human Cells anti-COVID-19 S-IgM Neutralizing Antibody
DL99728A-50ul	DL Develop	50 ul	EUR 210
Description: Spike glycoprotein; S glycoprotein; E2; Peplomer protein

Human Cells anti-COVID-19 S-IgA Neutralizing Antibody
DL99729A-100ul	DL Develop	100 ul	EUR 299
Description: Spike glycoprotein; S glycoprotein; E2; Peplomer protein

Human Cells anti-COVID-19 S-IgA Neutralizing Antibody
DL99729A-50ul	DL Develop	50 ul	EUR 210
Description: Spike glycoprotein; S glycoprotein; E2; Peplomer protein

Anti-β-Amyloid Neutralizing Antibody
71223	BPS Bioscience	100 µg	EUR 465
Description: Purified, recombinant, humanized Anti-β-amyloid (IgG1) antibody, expressed in HEK293 cells. This antibody reacts with human β-amyloid and has not been tested for cross-reactivity with other species.

Anti-CTLA4 (CD152) Neutralizing Antibody
71212	BPS Bioscience	100 µg	EUR 490
Description: Neutralizing recombinant human monoclonal antibody recognizing the extracellular domain of CTLA4 and blocking binding of CTLA4 to B7.1 and B7.2. This antibody recognizes human CTLA4 but does not bind to murine CTLA4. This antibody has not been tested for cross-reactivity with other species.

Human Cells anti-COVID-19 S-hIgG1 Neutralizing Antibody
DL99725A-100ul	DL Develop	100 ul	EUR 299
Description: Spike glycoprotein; S glycoprotein; E2; Peplomer protein

Human Cells anti-COVID-19 S-hIgG1 Neutralizing Antibody
DL99725A-50ul	DL Develop	50 ul	EUR 210
Description: Spike glycoprotein; S glycoprotein; E2; Peplomer protein

Anti- Interferon Beta Neutralizing Antibody
GWB-C275F9	GenWay Biotech	0.1 mg	Ask for price

Cytomegalovirus gB Late Neutralizing Antigen (CMV-LA gB Neutralizing) Antibody
abx411283-02mg	Abbexa	0.2 mg	EUR 678

Cytomegalovirus gB Late Neutralizing Antigen (CMV-LA gB Neutralizing) Antibody
abx411283-100g	Abbexa	100 µg	Ask for price

Cytomegalovirus gB Late Neutralizing Antigen (CMV-LA gB Neutralizing) Antibody
abx411283-25g	Abbexa	25 µg	EUR 487.5

human anti-CPV neutralizing mAb
E4A09V04	EnoGene	50ug	EUR 255
Description: Available in various conjugation types.

human anti-FPV neutralizing mAb
E4A09V05	EnoGene	50ug	EUR 255
Description: Available in various conjugation types.

Anti-PD-L1 (CD274) Neutralizing Antibody
71213	BPS Bioscience	100 µg	EUR 505
Description: Neutralizing recombinant chimeric murine/human monoclonal antibody recognizing the extracellular domain of PD-L1 and blocking the binding of PD-L1 to PD-1. This antibody has been shown to cross-react with mouse PD-L1. No other species have been tested.

Recombinant Anti-ACE2 Neutralizing Antibody
MBS8118898-002mg	MyBiosource	0.02mg	EUR 325

Recombinant Anti-ACE2 Neutralizing Antibody
MBS8118898-01mg	MyBiosource	0.1mg	EUR 580

Recombinant Anti-ACE2 Neutralizing Antibody
MBS8118898-5x01mg	MyBiosource	5x0.1mg	EUR 2460

Recombinant Anti-ACE2 Neutralizing Antibody
MBS8118901-002mg	MyBiosource	0.02mg	EUR 325

Recombinant Anti-ACE2 Neutralizing Antibody
MBS8118901-01mg	MyBiosource	0.1mg	EUR 580

Recombinant Anti-ACE2 Neutralizing Antibody
MBS8118901-5x01mg	MyBiosource	5x0.1mg	EUR 2460

Anti RBD Omicron Neutralizing Antibody (S2E12)
MBS1563191-005mg	MyBiosource	0.05mg	EUR 450

Anti RBD Omicron Neutralizing Antibody (S2E12)
MBS1563191-01mg	MyBiosource	0.1mg	EUR 275

Anti RBD Omicron Neutralizing Antibody (S2E12)
MBS1563191-5x005mg	MyBiosource	5x0.05mg	EUR 1710

IL-6 Neutralizing Antibody
MBS8102624-02mg	MyBiosource	0.2mg	EUR 280

IL-6 Neutralizing Antibody
MBS8102624-05mg	MyBiosource	0.5mg	EUR 375

IL-6 Neutralizing Antibody
MBS8102624-5x05mg	MyBiosource	5x0.5mg	EUR 1545

Anti-2019-nCoV Spike Neutralizing Antibody
E-AB-V1024-100uL	Elabscience Biotech	100uL	EUR 650
Description: Unconjugated

Anti-2019-nCoV Spike Neutralizing Antibody
E-AB-V1024-50uL	Elabscience Biotech	50uL	EUR 390
Description: Unconjugated

Anti-2019-nCoV Spike Neutralizing Antibody
E-AB-V1024-each	Elabscience Biotech	each	Ask for price
Description: Unconjugated

Anti-2019-nCoV Spike Neutralizing Antibody
E-AB-V1025-100uL	Elabscience Biotech	100uL	EUR 650
Description: Unconjugated

Anti-2019-nCoV Spike Neutralizing Antibody
E-AB-V1025-50uL	Elabscience Biotech	50uL	EUR 390
Description: Unconjugated

Anti-2019-nCoV Spike Neutralizing Antibody
E-AB-V1025-each	Elabscience Biotech	each	Ask for price
Description: Unconjugated

Anti-2019-nCoV Spike Neutralizing Antibody
MBS2563904-005mL	MyBiosource	0.05mL	EUR 390

Anti-2019-nCoV Spike Neutralizing Antibody
MBS2563904-01mL	MyBiosource	0.1mL	EUR 620

Anti-2019-nCoV Spike Neutralizing Antibody
MBS2563904-5x01mL	MyBiosource	5x0.1mL	EUR 2735

Anti-2019-nCoV Spike Neutralizing Antibody
MBS2563905-005mL	MyBiosource	0.05mL	EUR 390

Anti-2019-nCoV Spike Neutralizing Antibody
MBS2563905-01mL	MyBiosource	0.1mL	EUR 620

Anti-2019-nCoV Spike Neutralizing Antibody
MBS2563905-5x01mL	MyBiosource	5x0.1mL	EUR 2735

Cytomegalovirus gB Late Neutralizing Antigen (CMV-LA gB Neutralizing) Antibody (FITC)
abx411284-01mg	Abbexa	0.1 mg	EUR 610.8

Cytomegalovirus gB Late Neutralizing Antigen (CMV-LA gB Neutralizing) Antibody (FITC)
abx411284-100g	Abbexa	100 µg	EUR 425

DKK-1 Neutralizing Antibody
MBS8101470-02mg	MyBiosource	0.2mg	EUR 280

DKK-1 Neutralizing Antibody
MBS8101470-05mg	MyBiosource	0.5mg	EUR 375

DKK-1 Neutralizing Antibody
MBS8101470-5x05mg	MyBiosource	5x0.5mg	EUR 1545

Human SARS-CoV-2 Neutralizing Antibody ELISA Kit
abx365044-100g	Abbexa	100 µg	EUR 618.75

Human SARS-CoV-2 Neutralizing Antibody ELISA Kit
abx365086-100g	Abbexa	100 µg	EUR 618.75

NGF/NGFB Neutralizing Antibody
MBS8104707-02mg	MyBiosource	0.2mg	EUR 280

NGF/NGFB Neutralizing Antibody
MBS8104707-05mg	MyBiosource	0.5mg	EUR 375

NGF/NGFB Neutralizing Antibody
MBS8104707-5x05mg	MyBiosource	5x0.5mg	EUR 1545

NGF/NGFB Neutralizing Antibody
MBS8104710-02mg	MyBiosource	0.2mg	EUR 280

NGF/NGFB Neutralizing Antibody
MBS8104710-05mg	MyBiosource	0.5mg	EUR 375

NGF/NGFB Neutralizing Antibody
MBS8104710-5x05mg	MyBiosource	5x0.5mg	EUR 1545

Anti-Enterovirus 71 VP1 Neutralizing Antibody
E-AB-V1081-100uL	Elabscience Biotech	100uL	EUR 200
Description: Unconjugated

Anti-Enterovirus 71 VP1 Neutralizing Antibody
E-AB-V1081-200uL	Elabscience Biotech	200uL	EUR 300
Description: Unconjugated

Anti-Enterovirus 71 VP1 Neutralizing Antibody
E-AB-V1081-500uL	Elabscience Biotech	500uL	EUR 465
Description: Unconjugated

Anti-Enterovirus 71 VP1 Neutralizing Antibody
E-AB-V1081-each	Elabscience Biotech	each	Ask for price
Description: Unconjugated

Anti-Enterovirus 71 VP4 Neutralizing Antibody
E-AB-V1082-100uL	Elabscience Biotech	100uL	EUR 200
Description: Unconjugated

Anti-Enterovirus 71 VP4 Neutralizing Antibody
E-AB-V1082-200uL	Elabscience Biotech	200uL	EUR 300
Description: Unconjugated

Anti-Enterovirus 71 VP4 Neutralizing Antibody
E-AB-V1082-500uL	Elabscience Biotech	500uL	EUR 465
Description: Unconjugated

Anti-Enterovirus 71 VP4 Neutralizing Antibody
E-AB-V1082-each	Elabscience Biotech	each	Ask for price
Description: Unconjugated

Anti-Enterovirus 71 VP1 Neutralizing Antibody
MBS2563745-01mL	MyBiosource	0.1mL	EUR 235

Anti-Enterovirus 71 VP1 Neutralizing Antibody
MBS2563745-02mL	MyBiosource	0.2mL	EUR 310

Anti-Enterovirus 71 VP1 Neutralizing Antibody
MBS2563745-05mL	MyBiosource	0.5mL	EUR 455

Anti-Enterovirus 71 VP1 Neutralizing Antibody
MBS2563745-5x05mL	MyBiosource	5x0.5mL	EUR 2015

Anti-Enterovirus 71 VP4 Neutralizing Antibody
MBS2563746-01mL	MyBiosource	0.1mL	EUR 235

Anti-Enterovirus 71 VP4 Neutralizing Antibody
MBS2563746-02mL	MyBiosource	0.2mL	EUR 310

Anti-Enterovirus 71 VP4 Neutralizing Antibody
MBS2563746-05mL	MyBiosource	0.5mL	EUR 455

Anti-Enterovirus 71 VP4 Neutralizing Antibody
MBS2563746-5x05mL	MyBiosource	5x0.5mL	EUR 2015

Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AS35)
SAD-S35	ACROBIOSYSTEMS	100ug	EUR 2974.6
Description: Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AS35) (SAD-S35) is isolated from a SARS-CoV-2 infected patient and is recombinantly produced from human 293 cells (HEK293). This antibody recognizes the SARS-CoV-2 Spike Protein RBD domain and inhibits the interaction between SARS-CoV-2 RBD and ACE2 with an IC50 of 1.47 μg/mL using SARS-CoV-2 Inhibitor Screening Kit.Pseudovirus assay shows that this antibody has potent neutralizing activity against pseudovirus bearing SARS-CoV-2 Spike protein.

human anti-FPV/CPV neutralizing mAb
E409C40-h100	EnoGene	100μL	EUR 395
Description: Available in various conjugation types.

Human anti-FPV/CPV neutralizing mAb
MBS8576867-01mL	MyBiosource	0.1mL	EUR 475

Human anti-FPV/CPV neutralizing mAb
MBS8576867-01mLAF405L	MyBiosource	0.1mL(AF405L)	EUR 565

Human anti-FPV/CPV neutralizing mAb
MBS8576867-01mLAF405S	MyBiosource	0.1mL(AF405S)	EUR 565

Human anti-FPV/CPV neutralizing mAb
MBS8576867-01mLAF610	MyBiosource	0.1mL(AF610)	EUR 565

Human anti-FPV/CPV neutralizing mAb
MBS8576867-01mLAF635	MyBiosource	0.1mL(AF635)	EUR 565

IL17/IL17a Neutralizing Antibody
MBS8106122-02mg	MyBiosource	0.2mg	EUR 280

IL17/IL17a Neutralizing Antibody
MBS8106122-05mg	MyBiosource	0.5mg	EUR 375

IL17/IL17a Neutralizing Antibody
MBS8106122-5x05mg	MyBiosource	5x0.5mg	EUR 1545

HER3/ErbB3 Neutralizing Antibody
MBS8101672-02mg	MyBiosource	0.2mg	EUR 280

HER3/ErbB3 Neutralizing Antibody
MBS8101672-05mg	MyBiosource	0.5mg	EUR 375

HER3/ErbB3 Neutralizing Antibody
MBS8101672-5x05mg	MyBiosource	5x0.5mg	EUR 1545

HER3/ErbB3 Neutralizing Antibody
MBS8101673-02mg	MyBiosource	0.2mg	EUR 280

HER3/ErbB3 Neutralizing Antibody
MBS8101673-05mg	MyBiosource	0.5mg	EUR 375

HER3/ErbB3 Neutralizing Antibody
MBS8101673-5x05mg	MyBiosource	5x0.5mg	EUR 1545

HER3/ErbB3 Neutralizing Antibody
MBS8101674-02mg	MyBiosource	0.2mg	EUR 280

HER3/ErbB3 Neutralizing Antibody
MBS8101674-05mg	MyBiosource	0.5mg	EUR 375

HER3/ErbB3 Neutralizing Antibody
MBS8101674-5x05mg	MyBiosource	5x0.5mg	EUR 1545

HER3/ErbB3 Neutralizing Antibody
MBS8101675-02mg	MyBiosource	0.2mg	EUR 280

HER3/ErbB3 Neutralizing Antibody
MBS8101675-05mg	MyBiosource	0.5mg	EUR 375

HER3/ErbB3 Neutralizing Antibody
MBS8101675-5x05mg	MyBiosource	5x0.5mg	EUR 1545

Anti-2019-nCoV S-IgM Neutralizing Antibody
E-AB-V1026-100uL	Elabscience Biotech	100uL	EUR 425
Description: Unconjugated

Anti-2019-nCoV S-IgM Neutralizing Antibody
E-AB-V1026-200uL	Elabscience Biotech	200uL	EUR 750
Description: Unconjugated

Anti-2019-nCoV S-IgM Neutralizing Antibody
E-AB-V1026-50uL	Elabscience Biotech	50uL	EUR 260
Description: Unconjugated

Anti-2019-nCoV S-IgM Neutralizing Antibody
E-AB-V1026-each	Elabscience Biotech	each	Ask for price
Description: Unconjugated

Anti-2019-nCoV S-IgA Neutralizing Antibody
E-AB-V1027-100uL	Elabscience Biotech	100uL	EUR 425
Description: Unconjugated

Anti-2019-nCoV S-IgA Neutralizing Antibody
E-AB-V1027-200uL	Elabscience Biotech	200uL	EUR 750
Description: Unconjugated

Anti-2019-nCoV S-IgA Neutralizing Antibody
E-AB-V1027-50uL	Elabscience Biotech	50uL	EUR 260
Description: Unconjugated

Anti-2019-nCoV S-IgA Neutralizing Antibody
E-AB-V1027-each	Elabscience Biotech	each	Ask for price
Description: Unconjugated

Anti-2019-nCoV S-IgM Neutralizing Antibody
MBS2564402-005mL	MyBiosource	0.05mL	EUR 280

Anti-2019-nCoV S-IgM Neutralizing Antibody
MBS2564402-01mL	MyBiosource	0.1mL	EUR 420

Collectively, this high-resolution antibody repertoire evaluation demonstrated the influence evolution can have on BCRs in response to influenza virus vaccination, which may information future common influenza prophylactic approaches.